Attached To Peptide Or Protein Of 2+ Amino Acid Units (e.g., Dipeptide, Folate, Fibrinogen, Transferrin, Sp. Enzymes); Derivative Thereof Patents (Class 424/1.69)
-
Patent number: 9421233Abstract: The present invention relates to methods of using fungal mycobiome as a means of treating and/or diagnosing diseases in a subject. In one embodiment, the present invention provides a method of diagnosing inflammatory bowel disease based on the composition of fungal strains present in the gut of a subject, and treating the subject by administering a probiotic biotherapy. In another embodiment, the present invention provides a method of diagnosing a severe form of ulcerative colitis by detecting the presence of a deficiency in dectin-1 expression in s. fibuligera in the gut of a subject.Type: GrantFiled: April 26, 2013Date of Patent: August 23, 2016Assignee: Cedars-Sinai Medical CenterInventors: David M. Underhill, Iliyan D. Iliev
-
Patent number: 9421247Abstract: Compositions of matter and methods for making, storing and administering artificial blood substitutes. Artificial blood substitutes may have oxygen carriers that encapsulate an oxygen-binding compound in a polymer vesicle. Oxygen-binding compounds may include hemoglobin, myoglobin, or other oxygen binding compounds having characteristics similar to hemoglobin. Oxygen carriers may include nanoparticles, polymers and/or polymersomes comprising of poly(ethylene oxide)-block-poly(?-caprolactone) (PEO-b-PCL) and related diblock copolymers of poly(ethylene oxide)-block-poly(?-methyl ?-caprolactone) (PEO-b-PMCL). The oxygen carriers may have tunable oxygen-binding capacities, uniform and appropriately small size distributions, and human bloodlike viscosities and oncotic properties.Type: GrantFiled: July 24, 2014Date of Patent: August 23, 2016Assignee: VINDICO NANOBIO TECHNOLOGY INC.Inventors: P. Peter Ghoroghchian, Eric Ostertag
-
Patent number: 9421245Abstract: The present invention relates to compositions, methods and kits for delivery of active agents (X) to cells or tissues that express proteoglycans. More specifically, the present invention relates to conjugates comprising (HB-linker)n-Xm-(linker-HB)o, where HB is a heparin binding protein, X is an active agents such as a therapeutic protein (including a functional fragment or variant thereof), or a therapeutic small molecule, linker is a linker entity and m is an integer of at least 1, and n+o is an integer of at least 1. Other aspects relate to use of a HB-X conjugate in methods to deliver active agents to cartilage for the treatment of cartilage related disease and disorders, the use of the HB-X conjugate in methods to deliver active agents to neuronal tissues (e.g., brain and spinal cord) for the treatment of neurological disorders, and the use of the HB-X conjugates in methods for the treatment of eye conditions and disorders and inflammatory conditions and disorders.Type: GrantFiled: June 25, 2013Date of Patent: August 23, 2016Assignee: The Brigham and Women's Hospital, Inc.Inventors: Richard T. Lee, Parth Patwari, Francesco Loffredo, James Pancoast
-
Patent number: 9417240Abstract: One or more aqueous, near infrared emitting, high yield, highly photoluminescent, stable quantum dots conjugated to one or more biomarkers specific moieties. The conjugated quantum dots have an enhanced detection sensitivity and selectivity and may be formed using a novel and efficient method for conjugating one or more biomarker specific moieties to the quantum dots. The invention is further directed to a method for using the conjugated quantum dots for cancer detection in the margin of excised tissue.Type: GrantFiled: May 25, 2012Date of Patent: August 16, 2016Assignee: Drexel UniversityInventors: Wei-Heng Shih, Wan Y. Shih, Giang Au, Ari D. Brooks, Vanlila K. Swami
-
Patent number: 9408917Abstract: The disclosure provides a pharmaceutical composition. The pharmaceutical composition includes a chitosan with palmitoyl groups and an active agent. According to another embodiment, the pharmaceutical composition can further include a gelling accelerating agent. According to an embodiment of the disclosure, the active agent of the disclosure can be administered in the form of a nano-drug, liposome, micelle, or microparticle.Type: GrantFiled: June 25, 2013Date of Patent: August 9, 2016Assignee: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTEInventors: Maggie J. M. Lu, Yu-Wen Lo, Chih-Peng Liu, Chia-Wen Huang, Shuen-Hsiang Chou, Po-Hung Lai, Tsan-Lin Hu, Min-Ying Lin, Chia-Mu Tu
-
Patent number: 9387189Abstract: Compositions and methods for treating infectious diseases produced by biofilms are disclosed. More specifically, the present disclosure refers to pharmaceutical compositions which may be used for treating biofilm infections, specifically, biofilms formed by bacteria such as Pseudomonas, E. coli, Klebsiella, and other human pathogens. Pharmaceutical compositions may include a nutrient dispersion. Pharmaceutical compositions disclosed may employ chemotactic agents in order to disrupt biofilms and therefore enhance the antibiotic response. Pharmaceutical compositions disclosed may include suitable vehicles which may depend on the dosage form.Type: GrantFiled: May 22, 2013Date of Patent: July 12, 2016Assignee: Professional Compounding Centers of America (PCCA)Inventor: Andrew B. Glasnapp
-
Patent number: 9376690Abstract: The present disclosure is directed to compositions comprising templated nanoconjugates and methods of their use.Type: GrantFiled: November 1, 2010Date of Patent: June 28, 2016Assignee: NORTHWESTERN UNIVERSITYInventors: Chad A. Mirkin, David A. Giljohann, Weston L. Daniel, Joshua I. Cutler, Ke Zhang, Dan Zheng
-
Patent number: 9370546Abstract: N-acyldipeptide derivatives are described. Compositions comprising the N-acyldipeptide derivatives are therapeutically effective for topical or systemic administration to alleviate or improve conditions, disorders, diseases, symptoms or syndromes associated with a tumor, cancer, immune, nervous, vascular, musculoskeletal or cutaneous system, or other tissue or system in a subject.Type: GrantFiled: May 21, 2015Date of Patent: June 21, 2016Inventors: Ruey J. Yu, Eugene J. Van Scott
-
Patent number: 9314533Abstract: A series of peptides with divergent confirmations including structures of formula (1A), (1B), (2) and (3) are provided. In the formula, wherein U, G, A, B, R1, R2 and T are as defined in the specification. The divergent peptides disclosed in the present invention are characterized in a mineral binding affinity function.Type: GrantFiled: June 27, 2014Date of Patent: April 19, 2016Assignee: KAOHSIUNG MEDICAL UNIVERSITYInventors: Hui-Ting Chen, Kuang-Chan Hsieh, Je-Ken Chang, Gwo-Jaw Wang, Yin-Chih Fu, Mei-Ling Ho, Cherng-Chyi Tzeng
-
Patent number: 9289516Abstract: The present disclosure provides compositions and methods based on peptide-detectable agent conjugates that are useful for imaging beta cell mass.Type: GrantFiled: June 27, 2011Date of Patent: March 22, 2016Assignee: The General Hospital CorporationInventors: Ralph Weissleder, Thomas Reiner, Edmund J. Keliher
-
Patent number: 9283289Abstract: Encompassed are pharmaceutically acceptable compositions formulated for the topical or transdermal delivery of probes specific for cyclooxygenase-2 (COX-2) of human and non-human subjects. In particular, an activatable probe comprises a fluorescent moiety comprising a fluorophore attached to a compound having selective affinity for COX-2, and a removable fluorescence quencher linked to the fluorescent moiety by a cleavable linker. Upon delivery to a recipient subject, the activatable probe is localized and concentrated in tissues and cells with elevated levels of COX-2. The linker is cleaved to release the fluorescence quencher.Type: GrantFiled: July 1, 2013Date of Patent: March 15, 2016Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOInventors: Jayakumar Rajadas, Emilio Gonzalez, Hyejun Ra, Irfan Ali-Khan, Christopher Contag
-
Patent number: 9278995Abstract: Compounds having activity for lowering parathyroid hormone levels are described. In one embodiment, the compounds are comprised of a contiguous sequence of subunits, X1-X2-X3-X4-X5-X6-X7, wherein the X1 subunit comprises a thiol-containing moiety and the distribution of charge on the X2-X7 subunits provides the desired activity. Methods of using the compounds for treating hyperparathyroidism, bone disease and/or hypercalcemic disorders are also described, and in particular, methods for lowering plasma PTH and serum calcium are provided. The compounds can be used to treat subjects having, for example: primary, secondary or tertiary hyperparathyroidism; hypercalcemia of malignancy; metastatic bone disease; or osteoporosis.Type: GrantFiled: February 18, 2013Date of Patent: March 8, 2016Assignee: KAI PHARMACEUTICALS, INC.Inventors: Felix Karim, Amos Baruch, Derek Maclean, Kanad Das, Qun Yin
-
Patent number: 9266908Abstract: The inventive compounds are small molecule therapeutics that are potent inhibitors of Arginase I and II activity. The invention also provides pharmaceutical compositions of the inventive compounds and methods for using the inventive compounds for treating or preventing a disease or a condition associated with arginase activity.Type: GrantFiled: October 18, 2012Date of Patent: February 23, 2016Assignee: MARS, INCORPORATEDInventors: Michael Van Zandt, Adam Golebiowski, Min Koo Ji, Darren Whitehouse, Todd Ryder, Raymond Paul Beckett
-
Patent number: 9234007Abstract: Embodiments of the present disclosure provide for RGD mimetic ?-AApeptide compounds, ?-AApeptide compounds capable of binding an RGD binding site on integrin ?v?3, linear ?-AApeptide compounds, cyclic ?-AApeptide compounds and multimeric RGD mimetic ?-AApeptide compounds, methods of making each, and methods of using each, and the like. In embodiments, the RGD mimetic ?-AApeptide compounds can be used in imaging, diagnostics, and treatment of angiogenesis related conditions.Type: GrantFiled: June 18, 2013Date of Patent: January 12, 2016Assignees: UNIVERSITY OF SOUTH FLORIDA, WISCONSIN ALUMNI RESEARCH FOUNDATIONInventors: Jianfeng Cai, Youhong Niu, Weibo Cai, Hao Hong
-
Patent number: 9217027Abstract: The invention relates to thrombin inhibitors derived from the salivary glands of haematophagous arthropods and in particular to bivalent and trivalent thrombin inhibitors that act by interacting with thrombin at two or three different sites.Type: GrantFiled: June 18, 2008Date of Patent: December 22, 2015Assignee: Isis Innovation LimitedInventors: Maria Kazimtrova, R. Manjunatha Kini, Cho Yeow Koh
-
Patent number: 9211341Abstract: This invention provides Chelating Complex Micelles as a drug carrier. The Chelating Complex Micelles can load drugs without changing their structure, and therefore extend the half-life of drugs in the human body. The chelating complex micelles contain a metal ion core, at least one polymer, and at least one drug molecule. The metal ion is considered as a Lewis acid while polymer chain and drug molecules are referred to as Lewis bases. The drug molecule is linked to the polymer via forming coordinate bonds with metal ion, and then self-assembled to form chelating complex micelles as a drug carrier.Type: GrantFiled: June 17, 2014Date of Patent: December 15, 2015Assignee: ORIGINAL BIOMEDICALS CO., LTD.Inventors: Chau-Hui Wang, Chia-Hung Chen, Johnson Lin, Jing-Yi Chen, Wei-Chuan Liao
-
Patent number: 9200054Abstract: Provided are therapeutic and diagnostic somatostatin analogs including radiotherapeutic and radiodiagnostic reagents, and methods of making and use thereof.Type: GrantFiled: September 18, 2013Date of Patent: December 1, 2015Assignee: The Regents of the University of CaliforniaInventors: Murray Goodman, Sandra Blaj Moore
-
Patent number: 9193797Abstract: Described herein is novel isolated or synthetic peptides derived from a complementarity determining region hypervariable domain amino acid sequence of a humanized monoclonal antibody to NaPi2B transporter, as well as derivatives thereof, and a pharmaceutical composition and a method for inhibiting tumor growth or treating a tumor or cancer treating using the antitumor peptides and derivatives thereof.Type: GrantFiled: December 14, 2011Date of Patent: November 24, 2015Assignee: Recepta Biopharma S.A.Inventor: Luiz Rodolpho Raja Gabaglia Travassos
-
Patent number: 9180214Abstract: The present invention is directed to novel non-invasive diagnostic tools/compounds to image and treat cancers, especially cancers which overexpress GnRH such as breast cancer, prostate cancer and melanoma, among others, including metastatic breast cancer, prostate cancer and/or melanoma among numerous others in vivo. The novel imaging probes are capable of detecting cancerous cells, as well as their metastatic spread in tissues. The novel probes of the present invention will also be useful to initiate therapy for breast and/or prostate cancer, among other cancers, as well as monitor patients' response to chemotherapy treatments and other interventions or therapies used in the treatment of cancer, including metastatic cancer as otherwise described herein. Compounds according to the present invention may be used as diagnostic tools for diagnosing cancer as well as therapeutic agents for treating cancer and related secondary disease states and conditions.Type: GrantFiled: April 16, 2012Date of Patent: November 10, 2015Assignee: STC.UNMInventor: Yubin Miao
-
Patent number: 9173952Abstract: There is described herein compounds comprising a mitochondrial penetrating peptide (MPP) conjugated to an antimicrobial, and their method of use.Type: GrantFiled: May 27, 2011Date of Patent: November 3, 2015Assignee: The Governing Council of the University of TorontoInventors: Shana Kelley, Mark Pereira
-
Patent number: 9150602Abstract: A precursor used for labeling hepatocyte receptors and applied to radiotracers for imaging or pharmaceutical compositions for liver cancers is revealed. The precursor is a bifunctional compound. The bifunctional group includes a trisaccharide structure and a diamide dimercaptide (N2S2) ligand. The trisaccharide has high affinity to asialoglycoprotein receptors (ASGPR) on surfaces of hepatocytes while N2S2 ligand reacts with radioisotopes to form neutral complexes. Thus the precursor stays on surfaces of hepatocytes to provide radioisotope labeling or treatment effect of liver cancers.Type: GrantFiled: July 24, 2012Date of Patent: October 6, 2015Assignee: Atomic Energy Council, Institute of Nuclear Energy ResearchInventors: Show-Wen Liu, Yu Chang, Cheng-Fang Hsu, Ming-Che Tsai, Tsung-Hsien Chiang, Yueh-Feng Deng, Kuei-Lin Lu, Chih-Yuan Lin, Da-Ming Wang, Ching-Yun Li
-
Patent number: 9128080Abstract: The invention is directed to a modified T cell receptor (TCR) comprising an amino acid sequence of a wild-type (WT) TCR with no more than three amino acid substitutions, wherein the modified TCR, as compared to the WT TCR, (i) has an enhanced ability to recognize target cells when expressed by CD4+ T cells and (ii) does not exhibit a decrease in antigen specificity when expressed by CD8+ T cells. Polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, and pharmaceutical compositions related to the modified TCR also are part of the invention. Further, the invention is directed to methods of detecting a diseased cell in a host, methods of treating or preventing a disease in a host, and methods of identifying a candidate adoptive immunotherapy TCR.Type: GrantFiled: November 28, 2011Date of Patent: September 8, 2015Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Paul F. Robbins, Richard A. Morgan, Steven A. Rosenberg
-
Patent number: 9095601Abstract: A functional biologically active particle conjugate useful for diagnosis and treating cancer as a bioportal comprises a nanoscale particle having associated therewith an intracellular targeting ligand comprising a PNA, or another nuclease resistant oligonucleotide analog such as MOE-mRNA (2?-methoxyethyl mRNA) or LNA (locked nucleic acid), having a sequence that binds selectively to an uniquely expressed or overexpressed mRNA specific to the cancer or disease state in a living mammal. In one aspect the uniquely overexpressed target specific to the cancer or disease state is the unr mRNA which can be targeted by the antisense sequence PNA50.Type: GrantFiled: December 5, 2012Date of Patent: August 4, 2015Assignee: WASHINGTON UNIVERSITY IN ST. LOUISInventors: Matthew L. Becker, Huafeng Fang, Xiaoxu Li, Dipanjan Pan, Raffaella Rossin, Xiankai Sun, John Stephen Taylor, Jeffrey L. Turner, Michael John Welch, Karen L. Wooley
-
Patent number: 9089619Abstract: Hybrid nanocrystals able to reach specific targets in the body for treatment and biological imaging are provided, as well as methods of making and administering same for treatment of disease conditions and for bioimaging and radiotherapy. The hybrid nanocrystals and methods can be used alone or in combination with other treatment and imaging modalities.Type: GrantFiled: June 6, 2006Date of Patent: July 28, 2015Assignee: University of KentuckyInventor: Tonglei Li
-
Patent number: 9089618Abstract: Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human PAM4 antibodies. The antibodies show novel and useful diagnostic characteristics, such as binding with high specificity to pancreatic and other cancers, but not to normal or benign pancreatic tissues and binding to a high percentage of early stage pancreatic cancers. Preferably, the antibodies bind to pancreatic cancer mucins such as MUC1 or MUC5ac and are of use for the detection and diagnosis of early stage pancreatic cancer. In more preferred embodiments, the anti-pancreatic cancer antibodies can be used for immunoassay of serum samples, wherein the immunoassay detects a marker for early stage pancreatic cancer in serum. Most preferably, the serum is extracted with an organic phase, such as butanol, before immunoassay. Alternatively, immunoassay with PAM4 and anti-CA19.9 antibodies may be utilized to improve sensitivity for pancreatic cancer.Type: GrantFiled: June 24, 2014Date of Patent: July 28, 2015Assignee: Immunomedics, Inc.Inventors: David V. Gold, David M. Goldenberg
-
Patent number: 9073974Abstract: The present invention is drawn to cyclic RGD peptides linked via a disulfide bond, where the terminal cysteines are preferably in the D configuration. These peptides target ?v?3 integrin on tumor cells and neovasculatures and function as targeting agents for tumor diagnostic imaging and therapy. Compared with the commonly used RGD ligands, compounds of the present invention have improved targeting efficacy and lower nonspecific binding to normal organs. Moreover, the compounds of the present invention can be functionalized to conjugate imaging payload without decreasing binding strength.Type: GrantFiled: December 16, 2010Date of Patent: July 7, 2015Assignee: The Regents of the University of CaliforniaInventors: Kit S. Lam, Yan Wang, Wenwu Xiao
-
Patent number: 9072792Abstract: A generic structure for the peptides of the present invention includes A-X-B-C, where C is a cargo moiety, the B portion includes basic amino acids, X is a cleavable linker sequence, and the A portion includes acidic amino acids. The intact structure is not significantly taken up by cells; however, upon extracellular cleavage of X, the B-C portion is taken up, delivering the cargo to targeted cells. Cargo may be, for example, a contrast agent for diagnostic imaging, a chemotherapeutic drug, or a radiation-sensitizer for therapy. X may be cleaved extracellularly or intracellularly. The molecules of the present invention may be linear, cyclic, branched, or have a mixed structure.Type: GrantFiled: June 7, 2011Date of Patent: July 7, 2015Assignee: The Regents of the University of CaliforniaInventors: Tao Jiang, Emilia S. Olson, Michael Whitney, Roger Tsien
-
Patent number: 9067969Abstract: N-acyldipeptide derivatives are described. Compositions comprising the N-acyldipeptide derivatives are therapeutically effective for topical or systemic administration to alleviate or improve conditions, disorders, diseases, symptoms or syndromes associated with a tumor, cancer, immune, nervous, vascular, musculoskeletal or cutaneous system, or other tissue or system in a subject.Type: GrantFiled: October 31, 2012Date of Patent: June 30, 2015Inventors: Ruey J. Yu, Eugene J. Van Scott
-
Patent number: 9062123Abstract: The present invention relates to an adrenomedullin derivative including an adrenomedullin peptide, or a fragment thereof chelated or otherwise bound to at least one active agent. Examples of active agents include a paramagnetic element, a radioactive element and a fibrinolytic agent, among others. Paramagnetic agents have a distribution that is relatively easily shown through Magnetic Resonance Imaging (MRI). Radioactive agents have applications in imaging and delivery of radiations, depending on the specific element included in the active agent. Delivery of fibrinolytic agents mainly to a specific organ, such as for example to the lungs, allows to substantially improve the specificity and efficacy of thrombolytic therapy by allowing local delivery of the fibrinolytic agent, thereby reducing the risks of major bleeding in the therapy of the organ. If the organ is the lungs, a non-limiting example of pathology treatable with the fibrinolytic agent is pulmonary embolus.Type: GrantFiled: July 7, 2011Date of Patent: June 23, 2015Assignee: PLUMOSCIENCE INC.Inventors: Jocelyn Dupuis, Alain Fournier
-
Patent number: 9051379Abstract: SP1 and modified SP1 variant polypeptides capable of forming reversible molecular associations with substances, compositions-of-matter comprising same, and uses thereof are provided.Type: GrantFiled: July 9, 2006Date of Patent: June 9, 2015Assignees: Fulcrum SP Ltd., Yissum Research Development Company of the Hebrew University of JerusalemInventors: Amnon Wolf, Yehonathan Pouny, Ira Marton, Or Dgany, Arie Altman, Oded Shoseyov
-
Patent number: 9040020Abstract: The present invention relates to novel muteins derived from human lipocalin 2 (hNGAL) and related proteins that bind a given non-natural ligand with detectable affinity. The invention also related to corresponding nucleic acid molecules encoding such a mutein and to a method for their generation. The invention further relates to a method for producing such a mutein. Furthermore, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein.Type: GrantFiled: April 9, 2013Date of Patent: May 26, 2015Assignee: Technische Universitaet MuenchenInventors: Arne Skerra, Andreas Eichinger, Hyun-Jin Kim
-
Publication number: 20150139902Abstract: The present invention relates to a method of purification of [18F]-fluciclatide via solid phase extraction (SPE). The method is amenable to automation, and is suitable for use in conjunction with automated synthesizer apparatus—especially cassette-based synthesizers. Also provided are cassettes for carrying out the purification method.Type: ApplicationFiled: May 23, 2013Publication date: May 21, 2015Applicant: GE HEALTHCARE LIMITEDInventors: Torgrim Engell, Dimitrios Mantzilas, Julian Grigg
-
Patent number: 9035023Abstract: To provide a diagnostic and therapeutic medicament, a bombesin analog peptide antagonist conjugate is provided which has general Formula (I), wherein A is a metal chelator comprising at least one radionuclide metal, B is a spacer linked to N-terminal of C or a covalent bond and C is a bombesin analog peptide antagonist having a sequence as claimed, where further x is an integer from 1 to 3 and n is an integer from 1 to 6.Type: GrantFiled: February 27, 2009Date of Patent: May 19, 2015Assignee: Piramal Imaging, SAInventors: Helmut Maecke, Jean Claude Reubi, Rosalba Mansi
-
Publication number: 20150132220Abstract: Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compositions and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases.Type: ApplicationFiled: January 8, 2015Publication date: May 14, 2015Inventors: Philip E. Thorpe, Jin He
-
Publication number: 20150132219Abstract: There is provided a 177-Lu labelled peptide for site-specific targeting of the Urokinase Plasminogen Activator Receptor (uPAR) thereby enabling treatment of a cancer disease associated with high uPAR expression; e.g. treatment of colorectal cancer by administering to a patient an effective amount of the 177-Lu labelled peptide.Type: ApplicationFiled: May 3, 2013Publication date: May 14, 2015Inventors: Andreas Kjaer, Morten Persson, Michael Ploug
-
Patent number: 9017644Abstract: The present invention relates to dendrimer compositions configured for treating inflammatory disorders and autoimmune disorders, and related methods of synthesis. Specifically, the present invention relates to methods for treating rheumatoid arthritis with PAMAM dendrimers having functional ligands configured for treating rheumatoid arthritis (e.g., therapeutic agents, pro-drugs, targeting agents, trigger agents, imaging agents) (e.g., methotrexate).Type: GrantFiled: November 9, 2009Date of Patent: April 28, 2015Assignee: The Regents of the University of MichiganInventors: James R. Baker, Jr., Larry A. Sternson, David Repp, Deborah Ladenheim
-
Publication number: 20150110713Abstract: A method for treating cancer, preventing cancer or delaying the progression of a cancer in an animal or human comprising the step of: administering to the animal or the human having a cancer a composition in an amount effective to treat cancer, prevent cancer or delay the progression of cancer in the animal or the human. The composition comprises a pharmaceutically acceptable excipient, and ascorbate which is joined to a carrier structure containing an anti-cancer active agent, said carrier structure being capable of releasing the anti-cancer agent in the presence of a reactive oxygen species.Type: ApplicationFiled: December 22, 2014Publication date: April 23, 2015Inventors: Anthony Manganaro, Karen Rockwell
-
Patent number: 9011816Abstract: Example systems and methods enhance contrast in MRI images. To facilitate imaging of atherosclerotic plaques, arterial and venous, cardiac, and even tumor tissues and fibrosis, a fibrin-fibronectin complex or disease-related fibronectin specific MRI contrast agent (CLPD) has a specific binding affinity for fibronectin.Type: GrantFiled: March 25, 2011Date of Patent: April 21, 2015Assignee: Case Western Reserve UniversityInventors: Zheng-Rong Lu, Xueming Wu
-
Patent number: 9012372Abstract: The invention relates to the field of biomedical and pharmacological research, in particular to the area of immunology, allergies and autoimmune diseases. The inventors have shown that SWAP-70 is a higher-level regulator for STAT-6 and BCL-6, the regulator being specific for IgE production in B-cells by amplifying the effect of STAT-6 and antagonizing the effect of BCL-6. The inventors have observed no influence of SWAP-70 on the expression of other genes that are likewise regulated by STAT-6 and/or BCL-6. In summary, it can be concluded that SWAP-70 positively regulates IgE production by shifting the interaction of the two antagonists STAT-6 and BCL-6 with regulatory elements of the IgE gene in favor of the activator STAT-6. Based on said findings, the invention provides a screening method which allows for identifying novel active agents that specifically inhibit IgE production.Type: GrantFiled: April 14, 2011Date of Patent: April 21, 2015Assignee: Albonia Biotech, Inc.Inventors: Rolf Jessberger, Tatsiana Audzevich
-
Publication number: 20150104381Abstract: The present invention relates to a compound that inhibits the activity of a degrading enzyme for use in combination with a therapeutic or diagnostic compound, preferably a moiety conjugated peptide, in the diagnosis and/or treatment of a disease, in particular cancer, to enhance targeting of the therapeutic or diagnostic compound to the disease site.Type: ApplicationFiled: July 6, 2012Publication date: April 16, 2015Applicant: BioSynthema Inc.Inventors: Theodosia Maina-Nock, Berthold Artur Nock, Marion de Jong Hendriks
-
Publication number: 20150104388Abstract: This invention relates to novel analogs of pituitary adenylate cyclase-activating polypeptide (PACAP), which are agonists for the PACAP/vasoactive intestinal peptide (VIP) receptors: PAC1, VPAC1 and VPAC2 receptors. These PACAP analogs can be used as prophylactic/therapeutic agents for a wide range of medical disorders, including (but not limited to) cancer and autoimmune disease. These PACAP analogs can be coupled to suitable radionuclides and used in the localization, diagnosis and treatment of disseminated cancers and metastatic tumors, or coupled to small molecule therapeutics and used as vectors for targeted drug delivery. This invention also provides pharmaceutical compositions of one or more PACAP-like compounds of the invention either alone or in combination with one or more other prophylactic/therapeutic agents.Type: ApplicationFiled: December 22, 2014Publication date: April 16, 2015Inventors: David H. COY, Jerome L. MADERDRUT, Min LI
-
Patent number: 9005575Abstract: The present invention is directed to novel non-invasive diagnostic and therapeutic tools/compounds comprising a hybride cyclic peptide which utilizes a cyclic peptide chelating group wherein the compound binds to a MSH receptor to image and treat cancers, especially, melanoma, including metastatic melanoma in vivo. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these cancers. The novel imaging probes are capable of detecting cancerous melanoma cells, as well as their metastatic spread in tissues. This represents a quantum step forward in the diagnosis and treatment of melanoma, including metastatic melanoma using non-invasive molecular imaging techniques. The novel probes of the present invention will also be useful to initiate therapy for melanoma as well as monitor patients response to chemotherapy treatments and other interventions or therapies used in the treatment of melanoma/metastatic melanoma.Type: GrantFiled: May 28, 2010Date of Patent: April 14, 2015Assignee: STC.UNMInventors: Yubin Miao, Jianquan Yang
-
Patent number: 9005577Abstract: The present application is directed to radiolabeled imaging agents comprising a radiolabel, and a substrate, pharmaceutical compositions comprising radiolabeled imaging agents, and methods of using the radiolabeled imaging agents. The present application is further directed to methods of preparing the radiolabeled imaging agent. Such imaging agents can used in imaging studies, such as Positron Emitting Tomography (PET) or Single Photon Emission Computed Tomography (SPECT).Type: GrantFiled: April 30, 2009Date of Patent: April 14, 2015Assignee: Siemens Medical Solutions USA, Inc.Inventors: Hartmuth C. Kolb, Joseph C. Walsh, Kai Chen, Umesh B. Gangadharmath, Gang Chen, Vani P. Mocharla, Dhanalakshmi Kasi, Peter J. H. Scott, Qianwa Liang
-
Publication number: 20150093329Abstract: The invention provides methods and products, such as kits, useful for determining the apoptotic state of cells in an organism, comprising detecting the presence or abundance of at least one caspase affinity labeling agent in the cells of an animal into which at least one caspase affinity labeling agent has been introduced, wherein the presence or abundance of the caspase affinity labeling agent correlates with the apoptotic state of the cells.Type: ApplicationFiled: September 12, 2014Publication date: April 2, 2015Applicant: SEED RESEARCH AND DEVELOPMENT, LLCInventors: Gary Johnson, Brian W. Lee
-
Patent number: 8992886Abstract: Compositions, methods of using and methods of making a cyclic peptide analog imaging agent that includes at least portions of a peptide or protein that binds specifically to the GLP-1 receptor (GLP-1R) and the cyclic analog has one or more conformational restrictions including, but not limited to, lactam bridges, disulfide bridges, hydrocarbon bridges, and their combinations, salts and derivatives thereof wherein the cyclic analog is more stable than a non-cyclic analog when incubated in the presence of enzymes that degrade GLP-1 and have an increased serum half-live, wherein the cyclic analog comprises at least a portion of a GLP-1 peptide or at least a portion of an Exendin peptide salts, derivatives or combinations thereof.Type: GrantFiled: April 6, 2010Date of Patent: March 31, 2015Assignee: Board of Regents, the University of Texas SystemInventors: Jung-Mo Ahn, Xiankai Sun
-
Publication number: 20150086482Abstract: The present application discloses compositions and methods of use of peptide targetable constructs for detection, diagnosis and/or imaging of cancer. In preferred embodiments, the targetable construct comprises at least one hapten, at least one fluorescent probe, a chelating moiety and a group IIIA metal-18F complex attached to the chelating moiety. For in vivo use, the labeled targetable construct is used in conjunction with a bispecific antibody comprising at least one binding site for the hapten and at least one binding site for a tumor-associated antigen. Cancers may be detected, diagnosed and/or imaged by fluorescence spectroscopy and/or PET or SPECT. Preferably, imaging is performed in intraoperative, intraperitoneal, laparoscopic, endoscopic or intravascular procedures.Type: ApplicationFiled: December 9, 2014Publication date: March 26, 2015Inventors: Celeste Aida S. Regino, William J. McBride, Chien-Hsing Chang, David M. Goldenberg
-
Publication number: 20150086481Abstract: GUCY2C receptor ligands conjugated to diagnostic and/or therapeutic moieties, methods of making such GUCY2C receptor ligands conjugates, and methods of using such GUCY2C receptor ligands conjugates, such as in the diagnosis and/or treatment of Parkinson's disease, are described.Type: ApplicationFiled: July 27, 2012Publication date: March 26, 2015Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: Yosif Ganat, Lorenz Studer
-
Patent number: 8986650Abstract: The present invention concerns a Ga68 complex of formula FOLATE-(LINKER)i-NOTA-Ga68 in which: 1) FOLATE is a folate compound or a derivative thereof capable of targeting a folate receptor, 2) NOTA is a chelate capable of complexing Ga68 having a NOTA scaffold or derivatives thereof 3) LINKER is a chemical group linking FOLATE and NOTA 4) i is an integer chosen between 0 and 1 wherein NOTA is complexing Ga68.Type: GrantFiled: August 8, 2011Date of Patent: March 24, 2015Assignee: GuerbetInventors: Marc Port, Claire Corot, Thierry Gautheret
-
Patent number: 8986651Abstract: The present invention is directed to novel non-invasive diagnostic tools/compounds to image cancers, especially, melanoma, including metastatic melanoma in vivo. The present compounds exhibit enhanced uptake in cancerous cells and tissue and decreased renal uptake in kidney, evidencing favorable pharmacokinetics of compounds of the present invention. The compounds according to the present invention represent an advance in the diagnosis and treatment of melanoma, including metastatic melanoma using non-invasive molecular imaging techniques. The novel probes of the present invention are also useful for initiating therapy for melanoma as well as monitor patients' response to chemotherapy treatments and other interventions or therapies used in the treatment of melanoma/metastatic melanoma. Compounds according to the present invention may be used as diagnostic tools for a number of conditions and diseases states as well as therapeutic agents for treating such conditions and disease states.Type: GrantFiled: November 30, 2010Date of Patent: March 24, 2015Assignee: STC.UNMInventors: Yubin Miao, Haixun Guo
-
Publication number: 20150078999Abstract: Peptides having activity as protein binding agents are disclosed. The peptides have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R, R1, L1, L2, G, M, Y1 Y2 and SEQ are as defined herein. Methods associated with preparation and use of such peptides, as well as pharmaceutical compositions comprising such peptides, are also disclosed.Type: ApplicationFiled: June 20, 2014Publication date: March 19, 2015Inventors: James R. Heath, Rosemary Dyane Rohde, Arundhati Nag, Samir Das, Aiko Umeda